| Browse |
| Search |
| Future Titles |
Coming Soon
Original Report |
KGF promotes paracrine activation of the SCF/c-KIT axis from human keratinocytes to melanoma cells |
Francesca Belleudi, Giorgia Cardinali, Daniela Kovacs, Mauro Picardo and Maria Rosaria Torrisi |
| Abstract |
Expression of long-chain fatty acyl-CoA synthetase 4 in breast and prostate cancer is associated with sex-steroid hormone negativity. |
Marie E Monaco, Chad J Creighton, Peng Lee, Xuanyi Zou, Matthew K Topham and Diana M Staffornini |
| Abstract |
Curcumin promotes apoptosis, increases chemosensitivity and inhibits nuclear factor-kappa beta in esophageal adenocarcinoma. |
Wibisono Hartojo, Amy L Silvers, Dafydd G Thomas, Christopher W Seder, Lin Lin, Hyma R Rao, Zhuwen Wang, Joel K Greenson, Thomas J Giordano, Mark B Orringer, Alnawaz Rehemtulla, Mahaveer S Bhojani, David G Beer and Andrew C. Chang |
| Abstract |
Circulating miR-210 is a novel hypoxia marker in pancreatic cancer |
Allen Ho, Xin Huang, Hongbin Cao, Claudia Christman-Skieller, Quynh-Thu Le and Albert C. Koong |
| Abstract |
Pheophorbide a mediated photodynamic therapy triggers HLA class I-restricted antigen presentation in human hepatocellular carcinoma |
Patrick Ming-Kuen Tang, Ngoc-Ha Bui Xuan, Chun-Kwok Wong, Wing-Ping Fong and Kwok-Pui Fung |
| Abstract |
Transferrin receptor 2 is frequently and highly expressed in glioblastomas |
Alessia Calzolari, Luigi Maria Larocca, Silvia Deaglio, Veronica Finisguerra, Alessandra Boe, Carla Raggi, Lucia Ricci-Vitani, Francesco Pierconti, Fabio Malavasi, Ruggero De Maria, Ugo Testa and Roberto Pallini |
| Abstract |
Intratumor administration of the photosensitizer Pc 4 affords photodynamic therapy efficacy and selectivity at short drug-light intervals |
Thomas H. Foster, Benjamin R. Giesselman, Rui Hu, Malcolm E. Kenney and Soumya Mitra |
| Abstract |
An approach to the study of gene expression in hepatocarcinogenesis initiation |
Olga Beltran-Ramirez, Sergueï Sokol, Véronique Le-Berre, Jean M François and Saul Villa-Treviño |
| Abstract |
Review |
Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): Processes, limitations, and further proposals |
Terence O'Reilly and Paul MJ McSheehy |
| Abstract |
| Home |
| Register |
| Submit Manuscript |
| Submit Review |
| Manuscript Status |
| FAQs |
| Contributor Instructions |
| Scope |
| Editorial Board |
| Subscribe |
| Contact Us |